Michaël Beuve

Prof. Michaël Beuve

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
BGB. Gervais
B. Gervais
MBMichaël Beuve
Michaël Beuve
GOG.H. Olivera
G.H. Olivera
Mariel Elisa GalassiMariel Elisa Galassi
Mariel Elisa Galassi

18 August 2013 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
GBGérald Bertrand
Gérald Bertrand
MMMira Maalouf
Mira Maalouf
ABAntony Boivin
Antony Boivin
PBPriscillia Battiston-Montagne
Priscillia Battiston-Montagne
MBMichaël Beuve
Michaël Beuve
CRClaire Rodriguez-Lafrasse
Claire Rodriguez-Lafrasse

1 July 2005 in Chemical Physics Letters
Verified
Journal Article
Closed access
BGB. Gervais
B. Gervais
MBMichaël Beuve
Michaël Beuve
GOG.H. Olivera
G.H. Olivera
Mariel Elisa GalassiMariel Elisa Galassi
Mariel Elisa Galassi
RRR.D. Rivarola
R.D. Rivarola

6 January 2020 in Physica Medica
Verified
Journal Article
Closed access
WLWeibo Li
Weibo Li
ABAna Belchior
Ana Belchior
MBMichaël Beuve
Michaël Beuve
YCY.Z. Chen
Y.Z. Chen
SMS. Di Maria
S. Di Maria
YZY.B. Zhang
Y.B. Zhang

1 May 2009 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MMMira Maalouf
Mira Maalouf
GAGersende Alphonse
Gersende Alphonse
ACAnthony Colliaux
Anthony Colliaux
MBMichaël Beuve
Michaël Beuve
STSelena Trajkovic-Bodennec
Selena Trajkovic-Bodennec
CRClaire Rodriguez-Lafrasse
Claire Rodriguez-Lafrasse

23 January 2017 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
Micaela CunhaMicaela Cunha
Micaela Cunha
CMCaterina Monini
Caterina Monini
ETEtienne Testa
Etienne Testa
MBMichaël Beuve
Michaël Beuve
Particle therapy is increasingly attractive for the treatment of tumors and the number of facilities offering it is rising worldwide. Due to the well-known enhanced effectiveness of ions, it is of utmost importance to plan treatments with great care to ensure tumor killing and healthy tissues sparing. Hence, the accurate quantification of the relative biological effectiveness (RBE) of ions, used in the calculation of the biological dose, is critical. Nevertheless, the RBE is a complex function of many parameters and its determination requires modeling. The approaches currently used have allowed particle therapy to thrive, but still show some shortcomings. We present herein a short description of a new theoretical framework, NanOx, to calculate cell survival in the context of particle therapy. It gathers principles from existing approaches, while addressing some of their weaknesses. NanOx is a multiscale model that takes the stochastic nature of radiation at nanometric and micrometric scales fully into account, integrating also the chemical aspects of radiation-matter interaction. The latter are included in the model by means of a chemical specific energy, determined from the production of reactive chemical species induced by irradiation. Such a production represents the accumulation of oxidative stress and sublethal damage in the cell, potentially generating non-local lethal events in NanOx. The complementary local lethal events occur in a very localized region and can, alone, lead to cell death. Both these classes of events contribute to cell death. The comparison between experimental data and model predictions for the V79 cell line show a good agreement. In particular, the dependence of the typical shoulders of cell survival curves on linear energy transfer are well described, but also the effectiveness of different ions, including the overkill effect. These results required the adjustment of a number of parameters compatible with the application of the model in a clinical scenario thereby showing the potential of NanOx. Said parameters are discussed in detail in this paper.